Close

BioCryst Pharma (BCRX) Plunges 28% After Pausing Enrollment in BCX9930 Clinical Trials

April 8, 2022 9:38 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

BioCryst Pharma (NASDAQ: BCRX) Plunges 28% After Pausing Enrollment in BCX9930 Clinical Trials



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Trader Talk